Evidence map›Paper›PMID 25782102›Full record

ArticleJournal of thrombosis and haemostasis : JTH2015

Unconjugated bilirubin inhibits proteolytic cleavage of von Willebrand factor by ADAMTS13 protease.

R-N Lu, S Yang, H M Wu, X L Zheng

Open access · bronzeAbstract read
In one paragraph

Article in Journal of thrombosis and haemostasis : JTH, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. What's new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura.Hematology. American Society of Hematology. Education Program · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

R-N LuDivision of Laboratory Medicine, Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL, USA.
S YangDepartment of Pathology, Ohio State University, Columbus, OH, USA.
H M WuDepartment of Pathology, Ohio State University, Columbus, OH, USA.
X L ZhengDivision of Laboratory Medicine, Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL, USA.
The Ohio State University · USUniversity of Alabama at Birmingham · US

Funding

Novel Therapeutics for Acquired Thrombotic Thrombocytopenic PurpuraR01HL115187 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ZHENG, X. LONG · 2013 to 2016
$1.6M
FDA HHS R01 FD003932NHLBI NIH HHS R01 HL115187
6 · The paper itself

Abstract

backgroundBilirubin is a yellow breakdown product of heme catabolism. Increased serum levels of unconjugated bilirubin are conditions commonly seen in premature neonates and adults with acute hemolysis including thrombotic microangiopathy. Previous studies have shown that unconjugated bilirubin lowers plasma ADAMTS13 activity, but the mechanism is not fully understood.

objectivesThe study is to determine whether unconjugated bilirubin directly inhibits the cleavage of von Willebrand factor (VWF) and its analogs by ADAMTS13.

methodsFluorogenic, surface-enhanced laser desorption/ionization time-of-flight mass spectrometric assay, and Western blotting analyses were used to address this question.

resultsUnconjugated bilirubin inhibits the cleavage of F485-rVWF73-H, D633-rVWF73-H, and GST-rVWF71-11K by ADAMTS13 in a concentration-dependent manner with a half-maximal inhibitory concentration of ~13, ~70, and ~17 μmol L(-1) , respectively. Unconjugated bilirubin also dose-dependently inhibits the cleavage of multimeric VWF by ADAMTS13 under denaturing conditions. The inhibitory activity of bilirubin on the cleavage of D633-rVWF73-H and multimeric VWF, but not F485-rVWF73-H, was eliminated after incubation with bilirubin oxidase that converts bilirubin to biliverdin. Furthermore, plasma ADAMTS13 activity in patients with hyperbilirubinemia increased after treatment with bilirubin oxidase.

conclusionsUnconjugated bilirubin directly inhibits ADAMTS13's ability to cleave both peptidyl and native VWF substrates in addition to its interference with certain fluorogenic assays. Our findings may help proper interpretation of ADAMTS13 results under pathological conditions. Whether elevated serum unconjugated bilirubin has prothrombotic effect in vivo remains to be determined in our future study.

Indexed as

ADAM ProteinsADAMTS13 ProteinBilirubinBlotting, WesternDose-Response Relationship, DrugHumansHyperbilirubinemiaOxidoreductases Acting on CH-CH Group DonorsProtease InhibitorsProteolysisSpectrometry, Mass, Matrix-Assisted Laser Desorption-Ionizationvon Willebrand FactorADAM ProteinsADAMTS13 ProteinADAMTS13 protein, humanBilirubinbilirubin oxidaseOxidoreductases Acting on CH-CH Group DonorsProtease Inhibitorsvon Willebrand FactorADAMTS13 protein, humanhyperbilirubinemiathrombosisthrombotic microangiopathiesvon Willebrand factor

Identifiers

PMID25782102
PMCPMC4599575
OpenAlexW2082234262

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.